<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="25354">Mineralocorticoid</z:chebi> receptors (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRs</z:e>) are classically known to be expressed in the distal collecting duct of the kidney </plain></SENT>
<SENT sid="1" pm="."><plain>Recently it was reported that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> is identified in the heart and vasculature </plain></SENT>
<SENT sid="2" pm="."><plain>Although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression is also found in the brain, it is restricted to the hippocampus and cerebral cortex under <z:mpath ids='MPATH_458'>normal</z:mpath> condition, and the role played by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRs</z:e> in brain remodeling after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> remains unclear </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we used the mouse 20-min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model to examine the time course of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression and activity in the ischemic brain </plain></SENT>
<SENT sid="4" pm="."><plain>We found that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-positive cells remarkably increased in the ischemic striatum, in which <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> expression is not observed under <z:mpath ids='MPATH_458'>normal</z:mpath> conditions, during the <z:hpo ids='HP_0011009'>acute</z:hpo> and, especially, <z:hpo ids='HP_0011011'>subacute</z:hpo> phases after <z:hpo ids='HP_0001297'>stroke</z:hpo> and that the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-expressing cells were astrocytes that migrated to the ischemic core </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="9241">spironolactone</z:chebi> markedly suppressed <z:chebi fb="1" ids="18421">superoxide</z:chebi> production within the <z:mpath ids='MPATH_124'>infarct</z:mpath> area during this period </plain></SENT>
<SENT sid="6" pm="."><plain>Quantitative real-time RT-PCR revealed that <z:chebi fb="0" ids="9241">spironolactone</z:chebi> stimulated the expression of neuroprotective or angiogenic factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), whereas immunohistochemical analysis showed astrocytes to be cells expressing bFGF and VEGF </plain></SENT>
<SENT sid="7" pm="."><plain>Thereby the incidence of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was reduced </plain></SENT>
<SENT sid="8" pm="."><plain>The up-regulated bFGF and VEGF expression also appeared to promote endogenous <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and blood flow within the <z:mpath ids='MPATH_124'>infarct</z:mpath> area and to increase the number of neuroblasts migrating toward the ischemic striatum </plain></SENT>
<SENT sid="9" pm="."><plain>By these beneficial effects, the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was significantly reduced in <z:chebi fb="0" ids="9241">spironolactone</z:chebi>-treated mice </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="9241">Spironolactone</z:chebi> may thus provide therapeutic neuroprotective effects in the ischemic brain after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>